| ERA | electrical response activity; electroencephalic response audiometry; Electroshock Research Associati... |
|---|---|
| ERP | early receptor potential; effective refractory period; elodoisin-related peptide; endoscopic retrogr... |
| GCGR | glucagon receptor; glucocorticoid receptor |
| INSRR | insulin receptor-related receptor |
| IRR | insulin receptor-related receptor; intrarenal reflux |
| interstitial lung disease with increased volume | <radiology> Cystic fibrosis (CF), eosinophilic granuloma (EG), lymphangioleiomyomatosis (LAM) (12 Dec 1998) |
|---|---|
| tidal volume | The volume of air inspired or expired during each normal, quiet respiratory cycle. Common abbreviations are tv or v with subscript t. (12 Dec 1998) |
| elution volume | <chemistry> The amount of eluant which has passed through the column in column chromatography before a particular peak in an elution profile appears, or before a specific substance of interest comes out with the eluant, separated out of the original mixed substance. (09 Oct 1997) |
| end-diastolic volume | The amount of blood in the ventricle immediately before a cardiac contraction begins; a measurement of cardiac filling between beats, related to diastolic function. (05 Mar 2000) |
| end-systolic volume | The amount of blood in the ventricle at the end of the cardiac ejection period and immediately preceding the beginning of ventricular relaxation; a measurement of the adequacy of cardiac emptying, related to systolic function. (05 Mar 2000) |
| erythrocyte volume | Volume of circulating erythrocytes. It is usually measured by radioisotope dilution technique. (12 Dec 1998) |
| expiratory reserve volume | The extra volume of air that can be expired with maximum effort beyond the level reached at the end of a normal, quiet expiration. Common abbreviation is erv. (12 Dec 1998) |
| extracellular fluid volume | The fraction of body wate rnot in cells; about 25% of body weight. It consists of plasma water (4.5% of body weight), water between cells (interstitial water-lymph, 11.5% of body weight), water in dense bone and connective tissue (7.5% of body weight) and water secretions.See transcellular water, about 1.5% of body weight.. (05 Mar 2000) |
| flow-volume curve | The graph produced by plotting the instantaneous flow of respiratory gas against the simultaneous lung volume, usually during maximal forced expiration. (05 Mar 2000) |
| foliage volume | <botany> The space, expressed in cubic metres, occupied by a tree. (12 Nov 1997) |
| forced expiratory volume | Measure of the maximum amount of air during a forced vital capacity determination that can be expelled in a given number of seconds. It is usually given as fev followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity. (12 Dec 1998) |
| left ventricular volume overload | <radiology> VSD, patent ductus arteriosus, mitral incompetence, aortic incompetence (12 Dec 1998) |
| lung volume measurements | Measurement of the amount of air that the lungs may contain at various points in the respiratory cycle. (12 Dec 1998) |
| acetylcholine receptor antibodies | <neurology, investigation> A test used to measure the amount of antibodies to acetylcholine receptors on nerve endings. This is a diagnostic test for myasthenia gravis. A normal value is no antibodies in the bloodstream. Acetylcholine receptor (AChR) binding autoantibodies (i.e. Antibodies reactive with several epitopes other than the binding site for acetylcholine or alpha-bungarotoxin) are present in approximately 88% of patients with generalised myasthenia gravis, 70% of ocular myasthenia and in approximately 80% of myasthenia gravis in remission. Although serum concentrations of AChR binding autoantibodies do not in general correlate well with severity of weakness, there is typical decrease in concentration as weakness improves with immunosuppressive therapy. AChR blocking autoantibodies (i.e., antibodies reactive with the AChR binding site) are present in about 50% of patients with myasthenia gravis, 30% with ocular myasthenia gravis and 20% of myasthenia gravis in remission, AChR blocking autoantibodies are the only AChR autoantibodies present in about 1% of myasthenia gravis. AChR modulating autoantibodies (i.e., autoantibodies which cross-link AChRs and cause their removal from muscle membrane surfaces) are present in more than 90% of myasthenia gravis and occasionally are the only AchR autoantibodies detectable in mild, recent onset or ocular-restricted myasthenia gravis. Results for AChR modulating autoantibodies can be transiently false-positive due to curare-like drugs used during general anesthesia. AChR autoantibodies of one or more types are found in at least 80% of ocular myasthenia gravis. Although generally absent in neurological conditions other than myasthenia gravis(and consequently unlikely to cause confusion in neurodiagnosis), false-positive results for AChR autoantibodies occasionally occur in primary biliary cirrhosis, tardive dyskinesia, autoimmune thyroiditis, the elderly, amyotrophic lateral sclerosis patients treated with cobra venom and patients with thymoma in the absence of myasthenia gravis. Approximately 1% of patients with rheumatoid arthritis treated with D-penicillamine develop AChR autoantibodies and myasthenia gravis, both of which disappear when the drug is discontinued. Babies born to ~10% of myasthenia gravis mothers have a transient neonatal form of myasthenia gravis that responds well to anticholinesterase therapy and usually remits within 1 month as maternal IgG disappears. (29 Dec 1997) |
| amino acid receptor | <biochemistry> Ligand gated ion channels with specific receptors for amino acid transmitters. An extended protein superfamily that also includes subunits of the nicotinic acetylcholine receptor. (18 Nov 1997) |